


Accepted Manuscript

Mortality in Pulmonary Arterial Hypertension Patients Treated with Continuous Prostanoids

S.D. Bartolome, MD, N. Sood, MD, T.S. Shah, MD, K. Styrvoky, MD, F.T. Torres, MD, K.M. Chin, MD MSCS



PII: S0012-3692(18)30571-3

DOI: [10.1016/j.chest.2018.03.050](https://doi.org/10.1016/j.chest.2018.03.050)

Reference: CHEST 1673

To appear in: *CHEST*

Received Date: 21 November 2017

Revised Date: 29 January 2018

Accepted Date: 20 March 2018

Please cite this article as: Bartolome S, Sood N, Shah T, Styrvoky K, Torres F, Chin K, Mortality in Pulmonary Arterial Hypertension Patients Treated with Continuous Prostanoids, *CHEST* (2018), doi: 10.1016/j.chest.2018.03.050.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Word Count

Abstract: 246

Paper: 2483

Mortality in Pulmonary Arterial Hypertension Patients Treated with Continuous Prostanoids

Short running title: Mortality in PAH after prostanoids

Authors: Bartolome SD MD¹, Sood N MD², Shah TS MD¹, Styrvoky K MD¹, Torres FT MD¹, Chin KM MD
MSCS¹

1. Division of Pulmonary and Critical Care Medicine, UT Southwestern, Dallas, Texas
2. Division of Pulmonary and Critical Care Medicine, UT Health Science Center at Houston,
Houston, Texas

Contact Author

Kelly Chin MD

Kelly.chin@utsouthwestern.edu

Potential conflicts of interest:

Dr. Bartolome has received research support from Reata, Eiger, United Therapeutics, Geno and the NIH. She is on the speaker's bureaus for Bayer, Actelion and Gilead and has consulted for Bayer, Actelion and Gilead. Dr. Shah has received research support from Actelion, Bayer and the NIH and has served on speaker's bureau and advisory board for Gilead sciences. There were no conflicts reported by Dr. Kim Styrvoky. Dr. Torres has received research support from United Therapeutics, Medtronic, Bellerophon, NIH, ARENA pharmaceutical and Gilead and has performed consulting for Actelion, Bayer, SteadyMed, Genentech, Boehringer-Ingelheim, Mallinckrodt and Reata. Dr. Chin has received research support from Actelion, GENO, the NIH, SoniVie and United Therapeutics and has performed consulting for Actelion and United Therapeutics.

Funding and prior presentation: none

Download English Version:

<https://daneshyari.com/en/article/8962888>

Download Persian Version:

<https://daneshyari.com/article/8962888>

[Daneshyari.com](https://daneshyari.com)